



PRESS RELEASE

Ocumetics Technology Corp. provides update on preclinical studies

For Immediate Release

Calgary, Alberta – May 18, 2022. Ocumetics Technology Corp. (“**Ocumetics**”) (TSXV:“**OTC**”) is pleased to provide an update on the status of preclinical studies for its first product, the Bionic Lens.

Since January 2022, Ocumetics has been busy undertaking a series of studies using cadaver donor eyes to determine how Ocumetics’ optical technologies would fit in the human eye. These studies have led to design enhancements to perfect how the Bionic Lens conforms to the lens capsular bag of the human eye.

The studies, and resulting design enhancements, were supervised by Ocumetics’ regulatory approval expert, Dr. Barbara Fant, Ocumetics’ founder and Chief Scientific Officer, Dr. Garth Webb, and Chief Medical Officer, Dr. Doyle Stulting.

“We are focused on perfecting the design of the lens technology before we begin the regulatory approval process, which we expect will begin shortly,” said Dr. Barbara Fant.

Dr. Garth Webb added, “We have been experimenting with different lens materials, and combinations thereof, to ensure we have optimized the quality of the optics and the accommodation levels we are seeking in the lens technology. We have also been experimenting with different types of lens injectors to ensure the ophthalmologist can maintain control of the injection process during surgery.”

The ergonomics of installing the optical technologies has also been an emphasis over the past 4-6 weeks.

“We have received excellent feedback from the ophthalmologists performing the cadaver surgeries,” says Dr. Doyle Stulting. “We have used this feedback to ensure the process of inserting the Bionic Lens into the eye is as easy and intuitive as possible. If ophthalmologists enjoy the surgical process of installing the Bionic Lens into the patient’s eye, they are much more likely to recommend Ocumetics products to their patients.”

“It has been a busy few months since our last update,” said Ocumetics CEO, Dr. Mark Lee. “We could not be happier with the progress being made. Moreover, we remain on target for the first human studies, the Proof of Concept, to begin later this fall. All-in-all, very encouraging news for both our investors and the future users of Ocumetics’ optical technologies.”

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry - the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee
President and CEO
(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.